Amneal Pharmaceuticals AMRX
NASDAQ AMRX
$21.23 -0.15 (-0.70%)
At close: Nov 16, 2026 · 4:00 PM EST

Amneal Pharmaceuticals (AMRX) Net Income Attributable to Noncontrolling Interests (2017 - 2026)

Updated

Amneal Pharmaceuticals (AMRX) posted Net Income Attributable to Noncontrolling Interests of $19.76 million for Q3 2026, up 25.4% from $15.76 million a year earlier and up 65.3% from the prior quarter.

Analysis

Amneal Pharmaceuticals (AMRX) Net Income Attributable to Noncontrolling Interests (2017 - 2026) Analysis & Trends

For the trailing twelve months through Sep 30, 2026, Net Income Attributable to Noncontrolling Interests at Amneal Pharmaceuticals was $61.96 million, up 19.8% year-over-year; for FY2025, it was $55.88 million, up 29.9% from FY2024.

  • In prior years, Amneal Pharmaceuticals' Net Income Attributable to Noncontrolling Interests was $43.01 million in FY2024 (+21.9%), $35.27 million in FY2023, -$125.24 million in FY2022 and $9.55 million in FY2021.
  • The Q3 2026 figure stands as the highest quarterly Net Income Attributable to Noncontrolling Interests in data going back to Q2 2017.
  • On a year-over-year basis, Net Income Attributable to Noncontrolling Interests increased in seven of the last eight quarters, with growth averaging 32.1%.
  • The strongest year-over-year quarter for Net Income Attributable to Noncontrolling Interests in the past five years was Q4 2024, with growth of 94.9%; the weakest was Q2 2024, with a decline of 39.2%.
  • According to Business Quant data, Net Income Attributable to Noncontrolling Interests for the three prior quarters was $11.95 million (Q2 2026), $15.74 million (Q1 2026) and $14.5 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn -
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn -
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 2.00 Mn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn -1.00 Mn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn -
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn -
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 10.00 Mn
10 Amneal Pharmaceuticals 7.10 Bn 6.33 Bn 334.12 Mn 19.76 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 19.76 Mn
Jun 30, 2026 11.95 Mn
Mar 31, 2026 15.74 Mn
Dec 31, 2025 14.50 Mn
Sep 30, 2025 15.76 Mn
Jun 30, 2025 13.19 Mn
Mar 31, 2025 12.42 Mn
Dec 31, 2024 10.34 Mn
Sep 30, 2024 11.91 Mn
Jun 30, 2024 10.79 Mn
Mar 31, 2024 9.97 Mn
Dec 31, 2023 5.31 Mn
Sep 30, 2023 15.35 Mn
Jun 30, 2023 17.77 Mn
Mar 31, 2023 -3.15 Mn
Dec 31, 2022 -1.53 Mn
Sep 30, 2022 299,000.00
Jun 30, 2022 -119.27 Mn
Mar 31, 2022 -4.74 Mn
Dec 31, 2021 -14.08 Mn
API Access

Amneal Pharmaceuticals Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=AMRX&period=max&api_key=YOUR_API_KEY